LivingGLP1
Study S003257

A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects

Registration

Registration
NCT05943886
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
164
Start
2021-08-11
Primary completion
2023-02-17
Lead sponsor
Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Conditions
Healthy Subjects; Obesity; T2DM (Type 2 Diabetes Mellitus)
Interventions
DRUG:HEC88473 injection; DRUG:Placebo
Results posted
FALSE

Registered primary outcomes

  • Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose of HEC88473 [Baseline to day 15]
  • Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple dose of HEC88473 [Baseline to day 43]
  • Cmax [Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours]
  • AUC [Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0029053First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.
Zhang H, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
2025Other trialPMID 40175670DOIcites ClinicalTrials.gov:NCT05943886; registry reference DERIVED:40175670
R0029705Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.
Xiang L, Journal of hepatology
2025Randomized trialPMID 39709140DOIcites ClinicalTrials.gov:NCT05943886; registry reference DERIVED:39709140